Akoya Biosciences, Inc. (AKYA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AKYA currently has 49.7M outstanding shares. with limited dilution risk as only 7.57M additional shares (15.2%) are authorized for issuance. The company has minimally diluted shareholders by 0.67% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 08, 2025 |
POS AM filing: This is a POS AM filing for a registration statement on Form S-3, registering up to $150,000,000 of common stock, preferred stock, debt securities, warrants, and units, and up to $50,000,000 of common stock to be offered and sold pursuant to an equity distribution agreement. |
50M | 7.6M |
| May 13, 2025 |
10-Q filing | 49.7M shares outstanding |
50M | 7.6M |
| Mar 17, 2025 |
10-K filing | 49.4M shares outstanding |
49M | 7.6M |
| Nov 14, 2024 |
10-Q filing | 49.5M shares outstanding |
50M | 7.6M |
| Aug 06, 2024 |
10-Q filing | 49.4M shares outstanding |
49M | 7.6M |
| May 14, 2024 |
10-Q filing | 49.2M shares outstanding |
49M | 7.6M |
| Mar 05, 2024 |
10-K filing | 38.3M shares outstanding |
38M | 7.6M |
| Nov 09, 2023 |
10-Q filing | 49.0M shares outstanding |
49M | 7.6M |
| Aug 08, 2023 |
10-Q filing | 48.8M shares outstanding |
49M | 7.6M |
| Jun 12, 2023 |
8-K filing: Akoya Biosciences, Inc. completed an offering of 10,005,000 shares of common stock at a public offering price of $5.00 per share, resulting in estimated net proceeds of approximately $47.8 million for working capital and general corporate purposes. ($50.03M proceeds) |
38M | 7.6M |
| May 09, 2023 |
10-Q filing | 38.3M shares outstanding |
38M | 7.6M |
| Mar 07, 2023 |
10-K filing | 37.7M shares outstanding |
38M | 7.6M |
| Nov 17, 2022 |
S-3/A filing: This is an S-3/A filing, indicating an amendment to a previously filed S-3 registration statement. The filing pertains to a primary offering of securities, with the registrant undertaking responsibility as a seller to purchasers in the initial distribution, regardless of the underwriting method used. |
38M | 7.6M |
| Nov 08, 2022 |
10-Q filing | 37.9M shares outstanding |
38M | 7.6M |
| Nov 07, 2022 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, debt securities, warrants, and units with an aggregate offering price not to exceed $150 million. |
38M | 7.6M |
| Aug 09, 2022 |
10-Q filing | 37.6M shares outstanding |
38M | 7.6M |
| May 06, 2022 |
10-Q filing | 37.5M shares outstanding |
37M | 7.6M |
| Mar 15, 2022 |
10-K filing | 37.4M shares outstanding |
37M | 7.6M |
| Nov 09, 2021 |
10-Q filing | 37.2M shares outstanding |
37M | 7.6M |
| Aug 11, 2021 |
10-Q filing | 37.1M shares outstanding |
37M | 7.6M |
| May 19, 2021 |
10-Q filing | 37.1M shares outstanding |
37M | 7.6M |
| Apr 20, 2021 |
8-K filing: Akoya Biosciences, Inc. completed its IPO of 7,567,000 shares of its Common Stock at $20.00 per share, resulting in gross proceeds of approximately $151.3 million before deducting expenses. ($151.3M proceeds) |
19M | 7.6M |
| Apr 12, 2021 |
S-1/A filing: This is an S-1/A filing for an underwritten public offering of common stock with an option for the underwriters to purchase additional shares. |
19M | 7.6M |